Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection
Open Access
- 9 October 2008
- journal article
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (11) , 2426-2433
- https://doi.org/10.1111/j.1600-6143.2008.02362.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis CJournal of Hepatology, 2007
- The Impact of Residual and Unmeasured Confounding in Epidemiologic Studies: A Simulation StudyAmerican Journal of Epidemiology, 2007
- Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled StudyGastroenterology, 2007
- Histological Benefit of Retreatment by Pegylated Interferon Alfa-2b and Ribavirin in Patients with Recurrent Hepatitis C Virus Infection PosttransplantationAmerican Journal of Transplantation, 2007
- Benefit of Sustained Virological Response to Combination Therapy on Graft Survival of Liver Transplanted Patients with Recurrent Chronic Hepatitis CAmerican Journal of Transplantation, 2005
- Recurrent hepatitis C posttransplant: Early preservation injury may predict poor outcomeLiver Transplantation, 2005
- Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1Transplantation, 2004
- Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic studyLiver Transplantation, 2001
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- Recurrence of hepatitis C following orthotopic liver transplantation: a polymerase chain reaction and histological studyJournal of Hepatology, 1994